Problems of Radiation Medicine and Radiobiology

O. O. Lytvynenko¹, B. V. Sorokin², I. V. Halchak¹, O. P. Lishchenko¹, V. O. Demianov¹

¹ State Institution «National Research Center for Radiation Medicine, Hematology and Oncology of the
National Academy of Medical Sciences of Ukraine», 53 Yuriia Illienka Str., Kyiv, 04050, Ukraine
²Shupyk National Healthcare University of Ukraine, 9 Dorohozhytska Str., Kyiv, 04112 Ukraine

SYNCHRONOUS COLON CANCER ASSOCIATED WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA. CLINICAL CASE.

We present а rare clinical case of successful surgical treatment – combined left-sided hemicolectomy and cecal resection for colon cancer of two locations in a patient with idiopathic thrombocytopenic purpura, which, in our opinion, is due to radiation exposure is presented. It is shown that the biological effects of long-term ionizing radiation on critical organs can have a diverse nature both in terms of the time of occurrence and in their structure, which requires an individual approach, the involvement of related specialists and the necessary medical preoperative preparation for precise planning of surgical intervention taking into account all possible risks.
Key words: cecal cancer; colon cancer; idiopathic thrombocytopenic purpura; ionizing radiation.

Problems of Radiation Medicine and Radiobiology.
2024;29:465-472. doi: 10.33145/2304-8336-2024-29-465-472

full text

1. Shapochka FO, Zaletyuk SP, Hnydyuk MI. [Molecular biological features of breast cancer]. Clinical Oncology. 2013;(2):138-142. Ukrainian.  

2. Sivak LA, Veryovkina NO, Lyalkin SA. [Prognostic factors in breast cancer. The current state of the problem]. Clinical Oncology. 2014;(4):46-49. Russian.  

3. Naleskina LA, Lukyanova NYu, Chehun VF. [Molecular and genetic bases of clinical heterogeneity of breast cancer]. Oncology. 2017;19(3):171-179. Ukrainian.  

4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumors. Nature. 2000 (6797):747-752.
https://doi.org/10.1038/35021093  

5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad. Sci USA. 2001;98(19):10869-10874.
https://doi.org/10.1073/pnas.191367098  

6. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: towards a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65.
https://doi.org/10.1186/bcr2124  

7. Ponomareva OV. [Modern ideas about the possibilities of drug therapy for patients with triple negative breast cancer (ASCO 2011)]. Oncology. 2011;13(3):214-223. Russian.  

8. Abramovitz M., Bawick B.G., Willis S, Young B, Catzavelos C, Li Z, et al. Molecular characterization of formalin-fixed paraffin-embedded (FFPE) breast tumor specimens using a custom S12-gene breast cancer bead array-based platform. Br J Cancer. 2011;105(8):1574-1581.
https://doi.org/10.1038/bjc.2011.355  

9. Strehl JD, Wachter PL, Fasching PA, Beckmann MW, Hartmann A. Invasive breast cancer: recognition of molecular subtypes. Breast Care (Basel). 2011;6(4):258-264.
https://doi.org/10.1159/000331339  

10. O'Neill F, Madden SF, Clynes M, Crown J, Doolan P, Aherne ST, O'Connor R. A gene expression profile indicative of early stage HER2 targeted therapy response. Mol Cancer. 2013;12:69.
https://doi.org/10.1186/1476-4598-12-69  

11. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, …; ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v8-30.
https://doi.org/10.1093/annonc/mdv298  

12. Prat A, Cheang MC, Martin M, Carrasco E, Caballero R, Tyldesley S, et al. 100_PR Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;10(2):203-209.
https://doi.org/10.1200/JCO.2012.43.4134  

13. Kim HS, Park I, Cho HJ, Gwak G, Yang K, Bae BN, et al. Analysis of the potent prognostic factors in luminal-type breast cancer. J Breast Cancer. 2012;15(4):401-406.
https://doi.org/10.4048/jbc.2012.15.4.401  

14. Pracella D, Bonin S, Barbazza R, Sapino A, Castellano I, Sulfaro S, Stanta G. Are breast cancer molecular classes predictive of survival in patients with long follow-up? Dis Markers. 2013;35(6):595-605.
https://doi.org/10.1155/2013/347073  

15. Shevchenko TM, Gadzyuk PV, Bondar AM, Govodukha OYu. [Immunohistochemical study for diagnosis of infiltrative forms of breast cancer and determination of molecular subtype in women of different ages in Dnipro]. Regulatory Mechanisms in Biosystems. 2017;8(2):204-209. Ukrainian.
https://doi.org/10.15421/021732  

16. Ryabchikov DF, Vorotnikov IK. [Luminal breast cancer]. Moscow: GEOTAR - Media; 2021. 120 p. Russian.  

17. Parker JS, Mullins M, Cheahq MU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2023; 10;41(26):4192-4199.
https://doi.org/10.1200/JCO.22.02511  

18. Colomer R, Aranda-Lopez I, Albanell J, Garcia-Caballero T, Ciruelos E, Lopez-Garcia MA, et al. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2018;20(7):815-826.
https://doi.org/10.1007/s12094-017-1800-5  

19. Colomer R, Gonzalez-Farre B, Bsllesteros A, Peg V, Bermejo B, Perez-Mies B, et al. Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2024.
https://doi.org/10.1007/s12094-024-03541-1